Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Reigner

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Expert Opinion on Investigational Drugs|October 10, 2007
C.E.R.A.: pharmacodynamics, pharmacokinetics and efficacy in patients with chronic kidney diseaseFrancesco Locatelli, Bruno Reigner
CPT: Pharmacometrics & Systems Pharmacology|October 25, 2018
Pediatric Dosing of Ganciclovir and Valganciclovir: How Model-Based Simulations Can Prevent Underexposure and Potential Treatment FailureKarin Jorga, Bruno Reigner, Clarisse Chavanne, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|November 22, 2011
Effect of hemodialysis and hemofiltration on plasma C.E.R.A. concentrationsJohn K Leypoldt, Mahmoud Loghman-Adham, Paul Jordan, et al.
Journal of Clinical Pharmacology|February 25, 2010
Population pharmacokinetic/pharmacodynamic model for C.E.R.A. in both ESA-naive and ESA-treated chronic kidney disease patients with renal anemiaPascal Chanu, Ronald Gieschke, Jean-Eric Charoin, et al.
Current Medical Research and Opinion|October 27, 2007
Subcutaneous injection pain with C.E.R.A., a continuous erythropoietin receptor activator, compared with darbepoetin alfaAnne Pannier, Paul Jordan, Frank C Dougherty, et al.
British Journal of Clinical Pharmacology|March 13, 2003
Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patientsRonald Gieschke, Hans-Ulrich Burger, Bruno Reigner, et al.
Journal of Clinical Pharmacology|October 27, 2007
Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administrationSteven Fishbane, Anne Pannier, Xavier Liogier, et al.
Pharmaceutical Statistics|September 10, 2015
Bayesian adaptive dose-escalation procedures for binary and continuous responses utilizing a gain functionWai Yin Yeung, John Whitehead, Bruno Reigner, et al.
Current Medical Research and Opinion|June 3, 2008
The effect of severe hepatic impairment on the pharmacokinetics and haematological response of C.E.R.AViera Kupcová, Jan Sperl, Anne Pannier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2005
Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancerRoss Camidge, Bruno Reigner, Jim Cassidy, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Expert Opinion on Investigational Drugs|October 10, 2007
C.E.R.A.: pharmacodynamics, pharmacokinetics and efficacy in patients with chronic kidney diseaseFrancesco Locatelli, Bruno Reigner
CPT: Pharmacometrics & Systems Pharmacology|October 25, 2018
Pediatric Dosing of Ganciclovir and Valganciclovir: How Model-Based Simulations Can Prevent Underexposure and Potential Treatment FailureKarin Jorga, Bruno Reigner, Clarisse Chavanne, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|November 22, 2011
Effect of hemodialysis and hemofiltration on plasma C.E.R.A. concentrationsJohn K Leypoldt, Mahmoud Loghman-Adham, Paul Jordan, et al.
Journal of Clinical Pharmacology|February 25, 2010
Population pharmacokinetic/pharmacodynamic model for C.E.R.A. in both ESA-naive and ESA-treated chronic kidney disease patients with renal anemiaPascal Chanu, Ronald Gieschke, Jean-Eric Charoin, et al.
Current Medical Research and Opinion|October 27, 2007
Subcutaneous injection pain with C.E.R.A., a continuous erythropoietin receptor activator, compared with darbepoetin alfaAnne Pannier, Paul Jordan, Frank C Dougherty, et al.
British Journal of Clinical Pharmacology|March 13, 2003
Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patientsRonald Gieschke, Hans-Ulrich Burger, Bruno Reigner, et al.
Journal of Clinical Pharmacology|October 27, 2007
Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administrationSteven Fishbane, Anne Pannier, Xavier Liogier, et al.
Pharmaceutical Statistics|September 10, 2015
Bayesian adaptive dose-escalation procedures for binary and continuous responses utilizing a gain functionWai Yin Yeung, John Whitehead, Bruno Reigner, et al.
Current Medical Research and Opinion|June 3, 2008
The effect of severe hepatic impairment on the pharmacokinetics and haematological response of C.E.R.AViera Kupcová, Jan Sperl, Anne Pannier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2005
Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancerRoss Camidge, Bruno Reigner, Jim Cassidy, et al.
Pageof 2